Clinical trial · Observational
Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
A Prospective Study of Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA
NCT02833467CI-TRIAL-00040300unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Non-small-cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Thoracic Neoplasms | Thoracic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The detection rate of cancer related genes in multiple primary lung cancer patients by targeted next generation sequencing
- timeFrame
- 18 months
Secondary outcomes (3)
- measure
- The concordant and discordant frequency of genomic results between tumor tissue and circulating tumor DNA in multiple primary lung cancer patients
- timeFrame
- 18 months
- measure
- The relationship between disease free survival and genomic results in multiple primary lung cancer patients
- timeFrame
- 5 years
- measure
- The relationship between overall survival and genomic results in multiple primary lung cancer patients
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have given written informed consent * Histopathologically confirmed NSCLC * Considered multiple or multifocal primary lung cancer by clinical criteria Exclusion Criteria: * Malignant tumor history within the past 5 years * Patients who received any treatment prior to resection * Insufficient tumor tissue or blood sample
References
Publications (0)
Data not yet available
No reference posted for this study.